Compare LCID & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | AMRX |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2020 | 2018 |
| Metric | LCID | AMRX |
|---|---|---|
| Price | $6.23 | $12.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $15.71 | $15.60 |
| AVG Volume (30 Days) | ★ 15.4M | 1.3M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $595,271,000.00 | N/A |
| Revenue This Year | $71.67 | $4.48 |
| Revenue Next Year | $89.72 | $7.13 |
| P/E Ratio | ★ N/A | $57.32 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $7.02 |
| 52 Week High | $25.22 | $15.42 |
| Indicator | LCID | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 25.64 | 45.67 |
| Support Level | $2.11 | $12.50 |
| Resistance Level | $10.64 | $12.85 |
| Average True Range (ATR) | 0.65 | 0.49 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 1.40 | 28.01 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.